Join the 'Linzess' group to help and get support from people like you.
Posted 8 Aug 2014 by Drugs.com
FRIDAY, Aug. 8, 2014 – Newly released guidelines for the treatment of irritable bowel syndrome and a type of constipation known as chronic idiopathic constipation reveal a number of proven treatments for these two common conditions. "There's a greater variety of approaches which reflect a greater understanding of the disorders," said guidelines co-author Dr. Eamonn Quigley, chief of the division of gastroenterology and hepatology at Houston Methodist Hospital. "We now have a better opportunity to improve the lives of our patients," Quigley said. The guidelines are published in the August issue of the American Journal of Gastroenterology. An estimated 5 percent to 15 percent of the world's population has irritable bowel syndrome, a condition that can cause symptoms such as abdominal pain, diarrhea or constipation, cramping and bloating, and gas. It can affect people at any age but is ... Read more
Related support groups: Irritable Bowel Syndrome, Linzess, MiraLax, Dulcolax, Constipation - Chronic, Lactulose, Amitiza, Polyethylene Glycol 3350, Metamucil, Xifaxan, Bisacodyl, Rifaximin, Psyllium, Linaclotide, Duphalac, Konsyl, Generlac, Lubiprostone, Correctol, GlycoLax
Posted 18 Sep 2012 by Drugs.com
TUESDAY, Sept. 18 – A new drug significantly reduces the abdominal pain and constipation characteristic of certain types of irritable bowel syndrome, according to two new studies. Both phase 3 trials, published online Sept. 18 in the American Journal of Gastroenterology, formed much of the basis for approval of the drug, Linzess (linaclotide), by the U.S. Food and Drug Administration in August, said Dr. William Chey, lead author of one of the studies and co-editor-in-chief of the journal. "These are as good a set of results as we've seen on a drug for patients with constipation-predominant irritable bowel syndrome," said Chey, who is a professor of medicine at the University of Michigan Health System, in Ann Arbor. Both trials were funded by Forest Research Institute and Ironwood Pharmaceuticals, Inc., which make the drug. An Ironwood employee provided editorial assistance for both ... Read more